Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Janssen presents study to show long-term safety profile for Stelara®

The latest analysis presented by the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated long-term safety profile for ustekinumab drug, sold under the brand name Stelara® in older patients.

The new analysis that pooled safety data from 13 clinical studies across approved indications, was presented at United European Gastroenterology Week (UEGW).


Approved indications included adults with moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis.

These data show rates of key safety events among adults 60 years and older treated with the medicine for up to five years were similar to rates observed with placebo during the control phase of these trials.

Jansssen said the study represents an important group, as patients 60 years old and older are at a higher risk of disease and therapy-associated morbidity, which could lead to disease management challenges.

Key findings of the study included no - increased risk of malignancy with ustekinumab usage.

Professor Subrata Ghosh, chair and head of Department of Medicine, University College Cork, Ireland and lead study investigator of the pooled safety analysis, said: “Little has been intentionally explored about the safety profile of biologics in patients aged 60 and older with inflammatory bowel disease, as this population is often limited in number in clinical trials.”

“This analysis arms physicians with data to consider when treating older patients with ustekinumab given the safety profile observed across all approved indications.”

More For You

Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less
Day Lewis celebrates 50 years of delivering care to communities

The Patel family at the unveiling of the commemorative plaque ceremony

Day Lewis celebrates 50 years of delivering care to communities

Day Lewis honoured "the people, purpose and partnerships" as it celebrated 50 years of service by unveiling a commemorative plaque at the company’s support office in Croydon.

As one of the UK’s largest independent pharmacy chains, Day Lewis has delivered trusted care to communities across the country since it was founded in 1975, by brothers Kirit and JC Patel, who was on hand to unveil the plaque.

Keep ReadingShow less
CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

CPE said the committee’s discussions are fully shaped by pharmacy owners’ views and experiences

Pic credit: iStock

Pharmacy owners asked to share views on new contract and its financial implications

Pharmacy owners can share their thoughts on service developments and their financial security before the upcoming Community Pharmacy England (CPE) committee meeting to be held on June 25 and 26.

The new Community Pharmacy Contractual Framework (CPCF) was completed in March with the various service and regulatory changes still in progress.

Keep ReadingShow less